UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

                     DECEMBER 16, 2008 (DECEMBER 12, 2008)
                DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED)

                         COMPETITIVE TECHNOLOGIES, INC.
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

                                    DELAWARE
                                    --------
                 (STATE OR OTHER JURISDICTION OF INCORPORATION)

                           1-8696          36-2664428
                           ------          ----------
         (COMMISSION FILE NUMBER)     (IRS EMPLOYER IDENTIFICATION NO.)


          777 COMMERCE DRIVE, SUITE 100, FAIRFIELD, CONNECTICUT 06825
          -----------------------------------------------------------
               (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)(ZIP CODE)

                                 (203) 368-6044
                                 --------------
              REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE:

                                      N/A
         (FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))



ITEM  8.01

On  December  12,  2008, Competitive Technologies, Inc. (NYSE Alternext US: CTT)
issued  the  following  press  release:

COMPETITIVE  TECHNOLOGIES  REPORTS
FIRST  QUARTER  FISCAL  2009  RESULTS

FAIRFIELD,  CT  -  (DECEMBER  12,  2008)  - COMPETITIVE TECHNOLOGIES, INC. (NYSE
ALTERNEXT  US:  CTT)  today  announced  financial  results for the first quarter
fiscal  2009,  ending  October  31,  2008.

Expenses  were  substantially reduced for the fiscal first quarter ended October
31,  2008,  decreasing  61%  to  approximately  $1.1  million,  compared  to
approximately  $2.8  million  in  the prior year quarter. In September 2008, CTT
recorded  an  expense  reduction of $0.4 million received from Federal Insurance
Co.  under  its  theft  insurance policy relating to the Marcovitch, et al case.

"With  several  factors  contributing  to  improving  our  financial picture, we
believe  we  are  moving in the right direction toward restoring profitability,"
said John B. Nano, CTT's Chairman, President and CEO. "We continue to reduce our
costs  and  expect revenue to grow as we progress with our dynamic sales program
for  the  pain management medical device and other products and technologies. In
July  2008, we signed an equity financing arrangement with Fusion Capital for up
to  $5.0 million of cash through sale of our common stock, at our option. Of the
$5.0  million,  $4.9  million  remained  available  at  October  31,  2008."

Total  revenue  for  the  fiscal  first  quarter  ended  October  31,  2008, was
approximately  $0.1  million, compared to approximately $0.2 million in the same
period  of  the  prior  year.

"Sales  and  profit  prospects for our pain management medical device are highly
encouraging  based on the European CE Mark approval for sale of the device," Mr.
Nano  continued.  "We have signed four country-exclusive distribution agreements
for the device including the countries of India, Korea. Bangladesh and Malaysia.
We  have  responded  fully to the US FDA to their request for information on our
pending  510(k)  application for sale of the device in the United States. We are
continuing  our  review  and selection process for distributors in Europe, Asia,
the  U.S.  and  other  countries."

The  net loss for the quarter is approximately $1.0 million, or $0.12 per share,
a  62% improvement over the net loss of approximately $2.6 million, or $0.32 per
share,  for  the  prior  year  quarter.

Mr.  Nano  continued,  "We have advised the NYSE Alternext that we will submit a
plan  by January 2, 2009 that will demonstrate our ability to achieve, within 18
months,  compliance  with  the  exchange  listing  standard  below which we have
fallen.  We  are in financial non-compliance as our shareholders' equity is less
than  $4 million and we have had net losses in our three or our four most recent
fiscal  years.  A  "going  concern" statement describing our declining financial
condition,  with  our  plans  to  halt this decline, was included with our Forms
10-Q, filed June 12, 2008, and 10-K and auditors report, filed October 28, 2008.

"As the pain management medical device attains mature market levels, we believe
it will reach approximately $200 million per year in distributor sales to
hospitals and clinics. At that time, our revenue and profits from the device
will dramatically exceed those produced by any other technology in CTT's 40-year
history, resulting in approximately $20 million per year to CTT, with limited
related costs. CTT is aware of the needs expressed worldwide for treatment of
pain, and is pleased to be part of the solution a


we  aggressively  market  the  device  to  meet  those  needs. There is exciting
potential for the success of this device in the global pain management market; a
market  estimated  to  reach  $40  billion  by  2010."

CTT  has  exclusive  worldwide  rights  to  this  patented  medical  device,  a
non-invasive  method  for  rapid  treatment  of  high-intensity  oncologic  and
neuropathic  pain, including pain resistant to morphine and other drugs. The CTT
device  has  Medical  Device  CE  certification from the European Union allowing
sales  throughout  Europe,  and in all countries accepting the CE Mark. For more
information  on  the  device,  visit  www.CalmareTT.com  .
                                      -----------------

Mr. Nano noted, "The licensee for our nanoparticle bone biomaterial for human
spinal applications, Soteira Inc., completed a second fund raise for a total of
approximately $18 million in Series A and B financing. Soteria is seeking US FDA
and European CE Mark approval for the bone biomaterial. We believe FDA approval
will allow CTT to use the technology for other applications.

"CTT's  management  team  is  focused  on  creating  profitable  revenue growth,
restoring  shareholder  value,  building  global  alliances,  and maximizing the
dynamic  opportunities  of  our  products  and  technologies."

ABOUT  COMPETITIVE  TECHNOLOGIES,  INC.

Competitive Technologies, established in 1968, provides distribution, patent and
technology  transfer,  sales  and licensing services focused on the needs of its
customers  and  matching  those requirements with commercially viable product or
technology  solutions.  CTT  is  a  global leader in identifying, developing and
commercializing  innovative products and technologies in life, electronic, nano,
                 ------------------------------------
and  physical  sciences  developed by universities, companies and inventors. CTT
maximizes  the  value  of  intellectual assets for the benefit of its customers,
clients  and  shareholders.  Visit  CTT's  website:  www.competitivetech.net
                                                     -----------------------

Statements made about our future expectations are forward-looking statements and
subject to risks and uncertainties as described in our most recent Annual Report
on Form 10-K for the year ended July 31, 2008, filed with the SEC on October 28,
2008, and other filings with the SEC, and are subject to change at any time. Our
actual results could differ materially from these forward-looking statements. We
undertake no obligation to update publicly any forward-looking statement.

Direct inquiries to:     Johnnie D. Johnson, IR Services, LLC,
                         Tel: 860 434 2465, E-mail: jdjohnson@corpirservices.com
                                                    ----------------------------


                                   SIGNATURES

     Pursuant  to  the  requirements of the Securities Exchange Act of 1934, the
Registrant  has  duly  caused  this  report  to  be  signed on its behalf by the
undersigned  hereunto  duly  authorized.


                    COMPETITIVE TECHNOLOGIES, INC.
                                  (Registrant)

Dated: December 16, 2008          By: \s\ Johns B. Nano
                                  ---------------------
                    John B. Nano
                    Chairman and Chief Executive Offic